Found 5 matching trials
Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma PHASE2 This study is planned to prospectively evaluates the efficacy and safety of...
Show More Location
Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences, Tianjin, Tianjin 300020
Learn More & Join Trial
Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma PHASE2 This is a prospective, open-label, single-arm clinical trial evaluating a t...
Show More Location
Institute of Hematology & Blood Diseases Hospital
Learn More & Join Trial
Zanubrutinib, Obinutuzumab, and Lenalidomide (ZGR) in the Treatment of Newly Diagnosed Splenic B-cell Lymphoma With Prominent Nucleoli (SBLPN): A Prospective, Open-label, Single-arm Clinical Trial PHASE2 :The aim of this study was to analyze the safety and efficacy of Zanubrutin...
Show More Location
Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences
Learn More & Join Trial
Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL) PHASE2 This is a prospective, multiple-centers, open-label, single-arm clinical st...
Show More Location
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Learn More & Join Trial
Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma PHASE2 This study aims to preliminarily explore the efficacy and safety of the com...
Show More Status
Active Not Recruiting
Location
Institute of Hematology & Blood Diseases Hospital
Learn More & Join Trial